SEC Filings
State Street Holds 5% Of Geron Without Seeking To Influence Its Control
The holding comes against a quarterly profit, a trailing-year loss and a discontinued blood-cancer trial.
Geron (GERN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The holding comes against a quarterly profit, a trailing-year loss and a discontinued blood-cancer trial.
Earnings
Geron posted $1.4 million in quarterly net income as a cut to its returns reserve trimmed deductions from sales.
Markets
The blood-cancer drugmaker posted a small third-quarter profit on Rytelo growth and trimmed its 2026 operating expense guidance.
SEC Filings
The blood-cancer drugmaker swung from an $18.4 million loss a year earlier and lowered its 2026 operating expense range to $220 million to $230 million.
Markets
An independent committee advised Geron that its imetelstat study would likely miss its survival goal, and Nasdaq halted the stock Wednesday.